![]() The spike protein is composed of the S1 and S2 subunits 10, 11, 13. The transmembrane homo-trimer spike protein at the virus surface mediates receptor binding through interaction with cell entry receptor ACE2 14, 15, 16, 17, 18. The structural spike S protein playing a crucial role in eliciting the immune response during COVID-19 disease has been considered as the predominant viral antigen target for vaccine development 10, 11, 12, 13. Convalescent COVID-19 patients develop neutralizing anti-SARS-CoV-2 antibodies produced by the antiviral immune response 7, 8, 9. The main route for SARS-CoV-2 transmission is through respiratory droplets necessitating the implementation of effective control measures 2, 3, 4, 5, 6. The COVID-19 disease associated with the emerging SARS-CoV-2 infection is a pandemic public health threat since early 2020 with millions of deaths to date 1. SARS-CoV-2 virus is an enveloped RNA virus belonging to betacoronavirus genus of Coronoviridae family 1. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine comirnaty. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from comirnaty vaccine recipients but not COVID-19 recovered patients. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in comirnaty-vaccinated individuals. The Pfizer-BioNTech COVID-19 vaccine comirnaty is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. ![]() The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |